1. Home /
    2. Altai Protocol Library /
  2. New Indication: Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma

Altai Protocol Library

1041 protocols and counting

All protocols with references and links

All protocols reviewed by a Medical Oncologist/Hematologist

All protocols in major guidelines included

Ability to create your own protocols

Search Library Posts Search
Altai Protocol Library

New Indication: Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma

New Indication: Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma
Study:
  • Phase II-III, multicenter, randomized, double-blind, placebo-controlled study (SEAL)
  • Advanced dedifferentiated liposarcoma who received 2-5 lines chemotherapy
  • Selinexor (N: 188) or placebo (N:97) twice weekly in 6-week cycles
Efficacy:
  • No difference in OS
  • mPFS:2.8 vs 2.1 months, [HR:0.70 (0.52-0.95), p:0.011]
Safety:
  • Treatment related death: 4 (2.1%) vs 3 (3.1%)
  • Grade >= 3 AEs with selinexor: Decreased appetite (7.5%), fatigue (6.4%), nausea (5.9%)

J Clin Oncol. 2022 Apr 8;JCO2101829.

Gounder, Mrinal M et al. “Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial.

https://doi.org/10.1200/jco.21.01829

Reviewed by Hasan Çağrı Yıldırım, MD on May 30, 2022

Altai Chemo Planner

Quickly Prepare Accurate Chemotherapy Orders

Altai Chemo Planner employs Altai Protocol Library that includes over 1000 chemotherapy protocols for both Hematology and Oncology. You can find major guidelines' protocols, parenteral, and oral, in the library. Altai Protocol Library is frequently and regularly updated.

Learn More